IL17F and autoimmune disease: The results in Table 1 also indicate statistically significant differences in the concentrations of the following cytokines and chemokines in the plasma samples of patients at disease onset or relapse compared to those in remission after termination of treatment with CS: CSF1 (described above) and IL17F (proinflammatory cytokine interleukin-17F, enhancing inflammation and defense against infections, increased in autoimmune disease and infections).